CO6270212A2 - Compuestos y meyodos para modular el receptor farnesoide x (fxr) - Google Patents
Compuestos y meyodos para modular el receptor farnesoide x (fxr)Info
- Publication number
- CO6270212A2 CO6270212A2 CO10002335A CO10002335A CO6270212A2 CO 6270212 A2 CO6270212 A2 CO 6270212A2 CO 10002335 A CO10002335 A CO 10002335A CO 10002335 A CO10002335 A CO 10002335A CO 6270212 A2 CO6270212 A2 CO 6270212A2
- Authority
- CO
- Colombia
- Prior art keywords
- chlorine
- benzothienyl
- trifluoromethoxy
- indolyl
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- -1 trifluoromethoxy hydrogen Chemical group 0.000 abstract 11
- 239000000460 chlorine Substances 0.000 abstract 6
- 229910052801 chlorine Inorganic materials 0.000 abstract 6
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94997407P | 2007-07-16 | 2007-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270212A2 true CO6270212A2 (es) | 2011-04-20 |
Family
ID=39855171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10002335A CO6270212A2 (es) | 2007-07-16 | 2010-01-12 | Compuestos y meyodos para modular el receptor farnesoide x (fxr) |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8153624B2 (enExample) |
| EP (1) | EP2178851B1 (enExample) |
| JP (1) | JP5373788B2 (enExample) |
| KR (1) | KR101157334B1 (enExample) |
| CN (1) | CN101743232B (enExample) |
| AR (1) | AR067540A1 (enExample) |
| AT (1) | ATE539065T1 (enExample) |
| AU (1) | AU2008276236B2 (enExample) |
| BR (1) | BRPI0814571A2 (enExample) |
| CA (1) | CA2693406C (enExample) |
| CL (1) | CL2008002051A1 (enExample) |
| CO (1) | CO6270212A2 (enExample) |
| CY (1) | CY1112298T1 (enExample) |
| DK (1) | DK2178851T3 (enExample) |
| DO (1) | DOP2010000018A (enExample) |
| EA (1) | EA016475B1 (enExample) |
| EC (1) | ECSP109879A (enExample) |
| ES (1) | ES2376176T3 (enExample) |
| HR (1) | HRP20120048T1 (enExample) |
| IL (1) | IL202234A0 (enExample) |
| MA (1) | MA31683B1 (enExample) |
| MX (1) | MX2010000502A (enExample) |
| PE (1) | PE20090809A1 (enExample) |
| PL (1) | PL2178851T3 (enExample) |
| PT (1) | PT2178851E (enExample) |
| RS (1) | RS52216B (enExample) |
| SI (1) | SI2178851T1 (enExample) |
| SV (1) | SV2010003458A (enExample) |
| TN (1) | TN2010000028A1 (enExample) |
| TW (1) | TW200906823A (enExample) |
| WO (1) | WO2009012125A1 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| JP2014500319A (ja) * | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ファルネソイドｘ受容体を調節するための組成物および方法 |
| CN103370315A (zh) * | 2010-12-20 | 2013-10-23 | Irm责任有限公司 | 用于调控法尼醇x受体的组合物和方法 |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| HRP20201953T1 (hr) | 2013-09-11 | 2021-04-30 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b |
| JP6424231B2 (ja) * | 2013-11-05 | 2018-11-14 | ノバルティス アーゲー | ファルネソイドｘ受容体をモジュレートするための組成物および方法 |
| CN104045635A (zh) * | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| SG11201706347SA (en) | 2015-02-06 | 2017-09-28 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions for combination therapy |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| AU2016242861B2 (en) | 2015-03-31 | 2020-08-20 | Enanta Phamraceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| CA2981507A1 (en) | 2015-04-07 | 2016-10-13 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN107021958A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| TW201733582A (zh) | 2016-03-28 | 2017-10-01 | 大日本住友製藥股份有限公司 | Fxr促效劑及arb之組合醫藥 |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| PT3730487T (pt) | 2016-06-13 | 2022-07-22 | Gilead Sciences Inc | Derivados de azetidina como moduladores de fxr (nr1h4) |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| WO2018039386A1 (en) * | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic conditions and disorders |
| EP3512514A1 (en) * | 2016-09-14 | 2019-07-24 | Novartis AG | Novel regimes of fxr agonists |
| BR112019006651A2 (pt) | 2016-10-04 | 2019-07-02 | Enanta Pharm Inc | análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo |
| WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| US20180280394A1 (en) | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Methods of treating liver disease |
| JP2020515564A (ja) | 2017-03-30 | 2020-05-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物 |
| HRP20220026T1 (hr) * | 2017-04-12 | 2022-04-01 | Il Dong Pharmaceutical Co., Ltd. | Derivati izoksazola kao agonisti nuklearnog receptora i njihove uporabe |
| CN109265471B (zh) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| CN109320509B (zh) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
| CN111655680B (zh) | 2017-09-14 | 2024-03-05 | 阿德利克斯股份有限公司 | 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂 |
| KR102732835B1 (ko) | 2017-11-01 | 2024-11-22 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 가교된 비시클릭 화합물 |
| ES2944657T3 (es) * | 2017-11-01 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos de alqueno como moduladores del receptor farnesoide X |
| KR102731925B1 (ko) | 2017-11-01 | 2024-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물 |
| US11286252B2 (en) | 2017-11-01 | 2022-03-29 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| JP7228595B2 (ja) | 2017-11-01 | 2023-02-24 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしてのスピロ環化合物 |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| EP3730491B1 (en) * | 2017-12-22 | 2022-07-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CN110452235B (zh) * | 2018-05-08 | 2023-02-17 | 中国科学院上海药物研究所 | 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途 |
| US20210244744A1 (en) * | 2018-08-30 | 2021-08-12 | Terns Pharmaceuticals, Inc. | Treating liver disorders |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| KR20210130757A (ko) | 2019-02-15 | 2021-11-01 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 치환된 비시클릭 화합물 |
| JP7550777B2 (ja) | 2019-02-15 | 2024-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| EA202192244A1 (ru) | 2019-02-15 | 2022-01-24 | Бристол-Маерс Сквибб Компани | Замещенные амидные соединения, применимые в качестве модуляторов фарнезоидного x-рецептора |
| CN113439078B (zh) | 2019-02-19 | 2024-04-23 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| SG11202111502XA (en) | 2019-04-19 | 2021-11-29 | Shanghai Institute Of Materia Medica Chinese Academy Of Sciences | Fxr small molecule agonist and preparation method therefor and use thereof |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| AU2020284135A1 (en) | 2019-05-30 | 2022-01-06 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease |
| CA3139291A1 (en) | 2019-07-18 | 2021-01-21 | Jacky Vonderscher | Method for decreasing adverse-effects of interferon |
| EP4028008A4 (en) | 2019-09-12 | 2023-09-13 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4054567A4 (en) * | 2019-11-08 | 2024-01-10 | Terns Pharmaceuticals, Inc. | TREATMENT OF LIVER DISEASES |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| EP4090327B1 (en) | 2020-01-15 | 2025-03-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| MX2022014238A (es) * | 2020-05-13 | 2023-04-11 | Terns Pharmaceuticals Inc | Tratamiento combinado de trastornos hepáticos. |
| WO2022046779A1 (en) | 2020-08-25 | 2022-03-03 | Eli Lilly And Company | Polymorphs of an ssao inhibitor |
| IL301238A (en) * | 2020-09-11 | 2023-05-01 | Terns Pharmaceuticals Inc | Solid dispersion formulations of an fxr agonist |
| US20220135540A1 (en) * | 2020-10-15 | 2022-05-05 | Eli Lilly And Company | Polymorphs of an fxr agonist |
| MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
| US20240216364A1 (en) | 2021-04-28 | 2024-07-04 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| TW202327589A (zh) | 2021-11-11 | 2023-07-16 | 美商拓臻製藥公司 | 肝病之組合療法 |
| WO2023220404A1 (en) * | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
| CN115850152B (zh) * | 2022-12-20 | 2025-10-31 | 河北鼎泰制药有限公司 | 一种杂质A-7-imp3的制备方法及其用途 |
| KR20250166323A (ko) | 2023-04-07 | 2025-11-27 | 테른스 파마슈티칼스, 인크. | 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| ATE433106T1 (de) | 1998-12-23 | 2009-06-15 | Glaxo Group Ltd | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
| US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| US6967212B2 (en) * | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| EP1285914B1 (en) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
| JP4541883B2 (ja) | 2002-07-09 | 2010-09-08 | ブリストル−マイヤーズ スクイブ カンパニー | 抗糖尿病薬および抗肥満症薬として有用な置換へテロ環誘導体、並びに方法 |
| JP2006515838A (ja) | 2002-11-22 | 2006-06-08 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| AU2007212126B2 (en) | 2006-02-03 | 2012-07-19 | Eli Lilly And Company | Compounds and methods for modulating FX-receptors |
| US7846960B2 (en) | 2006-05-24 | 2010-12-07 | Eli Lilly And Company | FXR agonists |
| CA2651373A1 (en) * | 2006-05-24 | 2007-12-06 | Eli Lilly And Company | Compounds and methods for modulating fxr |
-
2008
- 2008-07-03 TW TW097125064A patent/TW200906823A/zh unknown
- 2008-07-11 EA EA201070148A patent/EA016475B1/ru not_active IP Right Cessation
- 2008-07-11 AU AU2008276236A patent/AU2008276236B2/en not_active Ceased
- 2008-07-11 AT AT08781651T patent/ATE539065T1/de active
- 2008-07-11 MX MX2010000502A patent/MX2010000502A/es active IP Right Grant
- 2008-07-11 CN CN2008800247651A patent/CN101743232B/zh active Active
- 2008-07-11 PL PL08781651T patent/PL2178851T3/pl unknown
- 2008-07-11 DK DK08781651.8T patent/DK2178851T3/da active
- 2008-07-11 WO PCT/US2008/069719 patent/WO2009012125A1/en not_active Ceased
- 2008-07-11 ES ES08781651T patent/ES2376176T3/es active Active
- 2008-07-11 EP EP08781651A patent/EP2178851B1/en active Active
- 2008-07-11 US US12/600,879 patent/US8153624B2/en active Active
- 2008-07-11 PE PE2008001168A patent/PE20090809A1/es not_active Application Discontinuation
- 2008-07-11 CA CA2693406A patent/CA2693406C/en not_active Expired - Fee Related
- 2008-07-11 BR BRPI0814571-7A2A patent/BRPI0814571A2/pt not_active IP Right Cessation
- 2008-07-11 RS RS20120099A patent/RS52216B/sr unknown
- 2008-07-11 KR KR1020107000896A patent/KR101157334B1/ko not_active Expired - Fee Related
- 2008-07-11 HR HR20120048T patent/HRP20120048T1/hr unknown
- 2008-07-11 JP JP2010517082A patent/JP5373788B2/ja active Active
- 2008-07-11 PT PT08781651T patent/PT2178851E/pt unknown
- 2008-07-11 SI SI200830514T patent/SI2178851T1/sl unknown
- 2008-07-14 CL CL2008002051A patent/CL2008002051A1/es unknown
- 2008-07-14 AR ARP080103026A patent/AR067540A1/es not_active Application Discontinuation
-
2009
- 2009-11-19 IL IL202234A patent/IL202234A0/en unknown
-
2010
- 2010-01-12 DO DO2010000018A patent/DOP2010000018A/es unknown
- 2010-01-12 CO CO10002335A patent/CO6270212A2/es not_active Application Discontinuation
- 2010-01-15 SV SV2010003458A patent/SV2010003458A/es not_active Application Discontinuation
- 2010-01-15 EC EC2010009879A patent/ECSP109879A/es unknown
- 2010-01-15 TN TNP2010000028A patent/TN2010000028A1/fr unknown
- 2010-02-11 MA MA32615A patent/MA31683B1/fr unknown
-
2012
- 2012-01-27 CY CY20121100098T patent/CY1112298T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6270212A2 (es) | Compuestos y meyodos para modular el receptor farnesoide x (fxr) | |
| AR117194A1 (es) | Compuestos de anillos fusionados | |
| AR102487A1 (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| AR110421A1 (es) | Derivados de pirazol como inhibidores de malt1 | |
| AR076752A1 (es) | Fenilureas y fenilamidas sustituidas como ligandos del receptor de vanilloides. | |
| AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
| MY144048A (en) | Chemical compound | |
| AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
| PE20110894A1 (es) | Derivados de pirimidin indol para el tratamiento de cancer | |
| AR071283A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| TW200604186A (en) | Compounds | |
| EA200702497A1 (ru) | Замещенные арилпиразолы для применения против паразитов | |
| CO6270328A2 (es) | Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b | |
| TW200602028A (en) | Compounds | |
| AR046445A1 (es) | Derivados de piridazin-3(2h)-ona | |
| NZ594641A (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
| CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| AR047890A1 (es) | Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 | |
| MX2016006685A (es) | Compuestos heterociclicos de n-acilimino. | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| ATE478859T1 (de) | Pyrazolderivat | |
| ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
| CO6260077A2 (es) | Pirimidinas biciclicas fusionadas | |
| EA200901175A1 (ru) | Способ получения 2,6-дихлор-4-(трифторметил)фенилгидразина, используя смеси дихлор-фтор-трифторметилбензолов | |
| PE20140226A1 (es) | Compuestos de triazolopiridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |